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The activity of the human papillomavirus type 18 minimal
constitutive enhancer (nucleotides 7508-7738)
studied in C33A cervical carcinoma cells Unidirec tiona 1
deletion mutations were performed to delineate the minimal
constitutive enhancer (MeEI region that is important for the
human papillomavirus type 18 expression. Maximum reduction in
the activity W::lS seen when region V (nucleotides 7673-773£\)
was deleted. The deletion mutant enhancer pBK8315 (nucleotides
7508-7664) expressed only 6.5 percent of the full length MCE
act.ivity. Though the expression was the least wi th this
mutant, all the regions appeared to be a requirement for the
full activity of the MCE. Gel retardation assays with the full
length MCE using C33A nuclear extract s:lowed two complexes.
Gel retardation assays were performed with deletion mutants
having regions I-IV (nucleotides 7508-7664) and region V using
C33A nuclear extract. The slowp.r migrating complex associated
with regions I-IV, while the fast",r migrating complex was
bound to region V. To identify the important motif of region
V and thereby the factor responsible for the exprt:ssion, site
directed mutagenesis performed. The ACTGCT motif at
nucleotides 7679-7684 was mutated. The in vivo activity of
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this site-directed mutant plasmid pBB155 was .educed to the
extent similar to pBK831S, signifying the importance of this
motif in the context of the full length MCE. When gel
retardation assay was performed with the site-directed mutant
using C))A nuclear extract, the faster migrating complex was
abolished, while the slower migrating -:omplex was present.
The mutant NCE competed with the slower migrating complex,
'IJhile the faster migrating complex was still present. The in
vitro binding assays correlated with the in vivo activity in
C))A cells. To further investigate the binding property of
the mutant motif, IN crosslinking was performed using C))A
nuclear extracts with NCE sequences from nucleotides 7667-
769). A band present with the wild type sequence ',.,1as absent
when the mutant sequence W<.LS used in t.he reaction. These
experiments demonstrate the importance of the ACTGCT motif at
nucleotides 7679-7684 and suggest the involvement of an ACTGCT
binding protein (ABP) in the regulation of HPV 18 NCE
activity.
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CHAPTER 1
In!;rpduc;l:i CD
1.1 Transc;rip!;ipnll1 Regulaticn in Eukaryotes
The pioneering work by Jacob and Monod (1961), on
the regulation of genes involved in lactose metabolism in
E.coli, laid the ground work for the since vastly progressed
research on transcriptional regulation. They demonstrated the
switching on of the synthesis of the enzyme [3-galactosidase as
a response to the presence of the substrate, lactose. This
synthesis was mediated by the increased transcription of this
gene.
In contrast to prokaryotic cells, which have a
single RNA polymerase enzyme, eukaryotes contain three
distinct RNA po Lyme rases . RNA polymerase I (RNAP I)
transcribes ribosomal RNA, RNAP II is the polymerase for
protein coding genes, whereas RNAP II! transcribes 5S rRNA and
tRNA genes (reviewed in Zawel & Reinberg, 1993).
The accurate initiation of transcription by RNAP I!
requires promoter-containing sequences upstream of the coding
region (Will et al., 1979). Promoters were identified by
mutational analysis of ovalbumin and adenovirus major late
gene coding sequences (Gannon et al., 1979; Corden et a1.
1980). The role of sequences called enhancers, ill
transcription was first demonstrated by Grosschedl ancl
Birnsteil (1980).
1.1.1 Promoter Elements in the Regulation of Transcription
The promoter sequence directs the accurate and
efficient initiation of tranl:lcription by RNAP II. PromoterH
can be classified as proximal elements and the TATA box. III
many protein coding genes, accurate transcription require::: the
presence of a TATA box, which is present about 25 bp upstream
of the transcription stal-t site. This directs the stable
formation of the pre-initiation complex The TATA element i:-;
believed to be responsible for determining the direction of
transcription along the DNA template. Transcription .i~
generally unidirectional Some promoters have a CCAA'r boy.
present about 80 bp upstream of the TATA box. This WiW
originally identified in the promoter of vertebrate rJlobin
genes (reviewed in Nussinov, 1990).
Promoters of many housekeeping genes lack '.rA'I'l\
boxes, and instead have GC rich elements that are often within
methylation-free islands (Bird, 1986). When a TATA box is not
present, RNAP II is fixed at the start site for the initiation
of transcription by an -initiator" element. It is a 17 ha:".lc
pair sequence cOI)'~aining the transcription start site. This
was first identified in the lymphocyte-specific terminal
deoxynucleotidyl transferase gene (Smale & 8altimore, 1989).
In addition to the TATA box, a promoter also has
upstream promoter elements (UPEs) which are 8-12 bp long
sequences (reviewed in Maniatis et al.,1987). The UPEs
function to increase the rate of transcription, while the TATA
box ensures accurate initiation of transcription. GC box and
CCAAT box are present in many genes transcribed by RNAP II.
The strength of the ~romoter is believed to depend on the
number of UPEs.
1.1.2 The Role of Enhancer Elements
Enhancers regulate promoters from a distance, in an
orientation independent fashion. The enhancer element was
first identified in SV40 (8anerji et a1., 1981 ). This 200 bp
DNA segment was positioned 200 bp upstream of the start site
and could enhance tr::mscription by 100 fold. Enhancers can
activate transcription when present in either orientation.
The basic unit of an enhancer element is called enhanson,
which is an individual binding site for transcriptional
activator proteins. By interchanging or duplicating the
units, new enhancer elements can be created (Ondek et al.,
1988; reviewed in Muller et a1., 1988).
Enhancers are believed to increase the rate of
transcription by increasing the density of RNA polymerase
enzyme over a linked gene (Weber & Schaffner, 1985). The
possible mechanisms to achieve activated transcription could
be by tracking or looping of DNA (reviewed in Wang & Giaever,
1988). According to the scanning model proposed by Moreau et
a1. (1981), the RNAP II, after binding to the enhancer, slides
in both directions along the DNA until it makes contact wi til
the start site. The looping model proposes the interaction of
enhancer and promoter through bound proteins, leading to the
looping out of the intervening DNA sequences. Tracking can
also induce DNA looping. The DNA structure is important for
the action of enhancers. Deletion of DNA corresponding to a
half helical turn is known to disrupt the enhancer activity,
whereas removal of multiples of ten bases between SV40
enhancer and its promoter had no effect on enhancer activity
(Schleif, R., 1988).
Enhancers can be categorized into two clast;es. The
enhancers that respond to changes in the environment
called inducible enhancers. The enhancers active in specific
tissues are called tissue-specific and the ones expressed at
certain stages of development are temporal enhancerz.
Inducible enhancers have been known to be present in genes
including heat shock, metallothionein genes. The activation
of steroid responsive genes by the binding of steroid receptor
proteins is well understood (reviewed in Maniatis al ..
1987; Pelham, 1982).
The expression of inununog1obu1in (Ig) genes in
lymphoid cells is a well studied example for tissue spe~ific
expression. Immunoglobulins are expressed in B cells and
lymphoid cells. The synergistic interaction between th'2
immunoglobulin promoter and enhancer controls the tissue-
specific expression of Ig genes (Muller et al., 1988). The
high level expression of insulin genes in pancreatic endocrine
cells is also controlled by the enhancer element. Tissue-
specific enhancers are involved in the expression of elastase
and chymotrypsin genes in the exocrine cells of pancreas
(Edlund et a1 .• 1985; Boulet et al., 1986).
1.1. 3 The Initiation Complex
Accurate transcription by RNA polymerase II requires
a preinitiation complex of a multifactor, nucleoprotein
assembly. This involves the assistance of auxiliary factors,
referred to as general transcription factors (GTFs). At least
five general transcription factors (TFIIA, TFIIB, TFIID. TFIIE
and TFIIFl are required to form an active initiation complex
(Dyn1acht et al., 1991; Buratowski et a1., 1989).
Transcription factor IID (TFIID) first
identified in Drosophila nuclear extracts (Parker & Topol,
1984) It is the only GT1" having DNA binding activity.
TFIlO binds to the TATA box of RNAP II promoters and directs
the orderly assembly of RNAP II and other GTFs to form the
initiation complex { reviewed in Conaway & Conaway, 1993l.
This complex is capable of initiating a basal level of
transcription. To medi.ate t..:-anscriptional regulation by
upstream factors, TATA box binding protein (TBP) ilBsociated
factors are required (reviewed in Tjian 1< Maniatis, 1994). In
eukaryotes, only one TFIID molecule exists with the exception
of Arabidopsis, where two genes encoding TFIID were found.
T1"IIO appears to recognize variallt TA'rA motif!~ with differ€>ot
affinities to mediate different responses. ThE! association ()f:'
other factors might enable this vursatility (Hoernandez, 1993;
Gasch et aI., 1990). The inner surface of 'f.'FIID interilcts
with the minor groove of the TATA box, leading to distortions
in the DNA. Other factors bind to the outer surface of Tf'IIO
(Klug, 1993).
TFIIA is known to bind to TFIIO-promoter complex,
early in the initiation process. TFIIA is believed to
counteract the negative regulators by compct ition, ilnd
stabilize the TFIID promoter complex: (reviE"wed 1n Conaway to
Conaway, 1993). rFIIB functions by recruiting RNAP II into
the initiation complex and also binds to the TFIID-DNA cornplr::x
directly. It is also believed to mediate interactions between
t.he initiation complex and upstream activators. TFIIB binding
to the initiat.ion complex is speculated to be the rate-
limiting step in the initiation (Buratowski, 1989; Lin &
Green, 19911. Tl"IIE is required for accurate in viera
transcription by RNAP II. Tl"IIE binds to the initiation
complex 'lfter RNAP II-TFIIF are bound to Tl"IIDAB (reviewed in
Zawel & Reinberg, 1993). TFIIF functions in bringing the RNAP
II enzyme to th<El initiation complex. It is also involved in
the elongation of transcription (Buratowski et al , 1989;
Bengal et al., 1991).
A recent study suggests that RNAP II may form a
multicomponent complex with some initiation factors before
binding to the promoter site (Kt'leske & Young, 1994). It is
believed that components of the initiation complex such as
TFIIA, TFIIB, TPIIE and TFIIH act as potential regulatory
targets for activators. The activation domain of VP16 is
known to interact with TFIIB (Tjian & Maniatis, 1994).
RNA polymerase II initiates transcription of
eukaryotic protein coding genes with the assembly of the pre-
initiation complex. The RNAP II of HeLa cells contains 10
subunits with molecular weights ranging from 240 to 10 kDa.
J\ unique C-terminal domain (CTD) is present in the largest
subunit of eukaryotic RNAP II, which is absent in prokaryotic
IUJAP or eukaryotic RNAP I and RNAP III. This CTD has multiple
repeats of consensus heptapeptide sequence containing serine
and threonine residues, which can be phosphorylated (reviewed
in Zawel & Reinberg, 1993). The CTD is known to bind <It t:le
promoter site by intercalating into DNA (Suzuki, 1990). The
CTD is believed to function by mediating transcriptional
activation through protein-protein functions as seen in
activation by Gal 4 (Allison & Ingles, 1989). The RNAP II is
in its unphosphorylated form when bound to the DNA ini tiat.ion
complex, at the time of transcription initiation. The CTD has
to be phosphorylated to !Je capable of transcript ~longation.
TFIIH in believed to contain a CTD kinase activity responsible
for the phosphorylation ILaybourn & Dahmus, 1990; Arias et
aL, 1991).
1.1.4 Transcription racton in the Roguh.t:$Qn of
TranscriptiQn
The regulation of gene expression is controlled by
the binding of nuclear factors to the conserved sequences
pr;E!sent in the regulatory region of t he gene. These
transcription factors bind to regulatory elements present.
within several hundred base pairs from the initiation site.
This regulation can be mediated by the different t.ranscript.ion
factors binding to their speci fie con8erved sequences
Broadly, the transcription factors are classified into
ubiquitous factors and tissue specific factors ( Polyanovsky
& Stepchenko, 19901. Deletion analysis of cloned transcription
factors have identified regions of the factors responsible for
DNA binding and transcriptional activation (reviewed in
Mitchell & Tjian, 1989).
The DNA binding zinc finger motif has about 30 amino
acids with two cysteine and two histidine residues that
stabilize the binding by a tetrahedral coordinatj':'r! with ZnJ •
ion. This motif is found in transcription factor Spl, which
activates transr:ription by binding to GC box present in the
promoter. Spl has two glutamine rich regions which are
responsible [or the transcriptional activation by Spl (Courey
& Tjian, 1988). The zinc finger motif is also seen in the DNA
binding domain of steroid hormone receptors. It was first
identified in RNAP III transcription factor TFIIIA which
regulates transcription of 55 RNA gene (reviewed in Mitchell
& Tj ian, 1989).
The homeodomain {HDl present in .. J, .... 'Jbiquitous Oct-1
factor recognizes the octomeric motif ATT'I'GcAT. This domain
stretches over 60 amino acids. The HD is present in homeotic
genes of Drosophila and vertebrates (Standt et a1., 1988;
reviewed in Mitchell & Tjian, 1989).
The transcription-replication factor CTF/NF-l binds
the GCCAAT box present in many genes. The DNA binding domain
is localized in its NH!-termina1 end which has a basic region
ideal for a-helical structure. The proline rich region
present in its COOH-terminus, activates transcription in
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association with zinc fingers of Spl (reviewed in Mitchell f.
Tjian, 1989).
The transcription factor C/EBP has a region of 35
amino acids in which every seventh amino acid is a leucine.
Similar regions are present in transcription factors GeNii,
Myc, F'os and Jun. These leucine rich regions form an Il-helix,
with the leucines occurring every two turns on the same side,
resembling a leucine zipper. Thi::; region facilit.atefj
dimerization of two protein molecules such that the adjacent
basic rich region can bind to DNA (Landschultz et al., 19RR).
The activation domain of transcription [acton; is
distinct from their DNA binding domain. Though DNA binding
domain is essential for transcriptional activation, it is not
sufficient without the ac:tivation domain of the fac:tor. Th~
yeast transcription factor Gal4 has two acidic regions which
can form amphipathic a-hE:=lical structure, with negative.
charges on one side of the helix available for contact with
another protein (reviewed in Mitchell & Tjian, 1989; Hope I.
Struhl, 1986).
1.2 Pap!llamayirus..
Papillomaviruses small, enveloped,
icosahedral double stranded circular viruses containing DNA ()f
11
about 8,000 base pair&. They belong to the sub-family
papillovirinae IFields, 19901.
The study of papi110maviruses gained importance
after the demonstration of the role of cottontail rabbit
papillomavirus in the etiology of epithelial neoplasia.
Later. the association of human papillomavirus with
epidermodysplasia verruciformis established the causative role
of papillomaviruses in humans (reviewed in Sousa et al.,
1990) .
More than 6S types of HPVs have been classified
based on the species of origin and the lack of homology with
other papillomaviruses from the same species (Payne et al..
1993; DeVilliers, 1989). Papillornaviruses are highly species-
specific and tissue-specific. Vegetative growth of the
viruses is sec" only in the nucleus of differentiated
keratinocytes of epithelia. The viral particles are found
only in the superficial layers of the epithelium (Broker"
Botchan, 1986; Pfister. H.. 1987).
Human papillomaviruses can be categorized as low
risk and high risk HPVs. HPV 6 and HPV 11 are present in
benign warts. exophytic condylomas but absent in high grade
neoplasias. The high risk HPV 16 and HPV 18 are predominantly
seen in high grade neoplasias of the anogenital region and
invasive cancers of the cervix. vulva. penis and anus (Sang"
Barbosa, 1992). Transfection of DNA from HPV 16 and HPV 18
L~
into primary human keratinocytes can immortalize the cells,
whereas HPV 6 and HPV 11 DNA fail to immortalize cells, Jeacli1l9
to senescence (Woodworth et al., 1989).
1.2.1 The HPV Gflnom8
The Bovine Papillomavirus 1 is taken <HI the
prototype virus for PVs. The genome has ten open rending
frames (ORFs), 8 early ORFs and 2 late ORFs as in fig 1. Th<..'
ORFs are located on one strand of the viral DNA unci
transcripts are encoded from this strand. The L ORFs expreSL;
only in terminally differentiated cells, whereas the E ORF:;
are expressed in non-productively infected and transformed
cells (Chen et al., 1982; Baker & Howley, 19B7). The HPV DNlI
is' found integrated into cellular ON'" in most HPV positive
cervical carcinoma cell lines, while HPV DNA is present
extrachrornosomally in benign lesions (Durst et al., 19R5).
The El ORF is the largest ORF and is well conr.ervccl
in all the papillomaviruses. The El ORF encodes a modulator
protein which is essential for the stable establishment I'Jl
plasmid ON"'. The regulator El-R, encoded by 81 ORf, j:-)
involved in the replication of DNA. The E1·R gene is believed
to be involved in DNA amplification as seen in the growth
arrested cells (Lusky & Botchan, 1986; Burnett et al., 198');
Ustav &. Steinland, 1991).
rig.!.
Schematic diagram of HPV 18 genome organization, The upstream
regulatory region (URR) is situat:.ed between Late (Ll I open
reading frame (ORF) and Early IE) 6 ORF. The 230 bp minimal
constitutive enhancer (HeE) is present in the URR (Butz &.
Hoppe-Seyler, 1993).
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The disruption of HPV 16 El gene is believed to increase the
viral immortalization capacity, since a HPV 16 DNA clone
isolatp.d from a cervical carcinoma contained a deletion,
re!,ulting in a frameshift mutation of the El gene. Mutation
of either the E1 or the E2 gene is believed to impart a high
immortalization efficiency for HPV 16 (Rornanczuk & Howley,
1992)
The E2 gene products are involved in regulatir.g
viral transcription and replication. The BPV-l E2
transact iva tor stabilizes the replication pre-initiation
complex by stimulating the binding of El replication protein
to the replication site and thereby activates DNA replication
(Yang et al., 1991). The E2 ORF of BPV 1 encodes a
transdctivator from full length ORF and two transcriptional
repressors from the 3' end of ORF. The c-terminal region of
the transactivator and repressor proteins is capable of
forming dimers to bind to DNA. This dimerization between
transactivator and repressor may lead to the formation of
inactive heterodimers (McBride et a1., 1989). The BPV-l E2
transactivating protein can stimulate HPV 18 long control
region and also repress the same. The binding of E2 protein
between the CAAT and TATA element of the HPV 18 long control
region may lead to sterica1 hindrance of the initiation
complex (Thierry & Yanb·, 1987). E2 protein is known to
compete with Spl and repress the E6 promoter of HPV 16 (Tan et
16
al., 1991 J . The role of E2 QRF in the immortalization of
cervical keratinocytes has been suggested, since HPV 16 with
a mutation in the E2 ORF was unable to inunortalize (Storey et
al., 1992)
HPV 16 E4 protein has been reported to be present jn
cutaneous warts. This expression confined to the areas of
epithelium expressing the Ll capsid protein. Unlike the
classical DNA virus early proteins, the HPV E4 gene products
are believed to playa role in virus maturation (Crum et ill.,
1990; Doorbar et a1. 1986).
The E5 protein is the smallest viral transforming
protein, with a molecular mass of 7 kOa containing 44 amino
acids. The ability of BPV to transform fibroblasts in vitl"O
is due to the E5 protein. The E5 gene from both BPV ilnd l-lPV
16 can transform established epidermal keratinocytes. The
transforming activity is encoded in its c-terminal domain
(reviewed in Sousa et al., 1990; Leptak et al., 1991)
1. 2.2 "Pya.in the EtiQ10gy of Cerv.ical Cancer
Research on the role of HPVs in the causation of female
genital tract infections has been intensively pursued avec the
years. The association of HPVs with benign papillarnatou~~
lesions of the skin, plantar warts, flat warts, genitcll
condylamas, epidermodysplasia verrucifocmis is well documented
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(Howley. 1982). The exposure of uterine cervix to HPV. leads
to the formation of genital wart like lesions. The
precancerous lesions of genital warts are referred to as
cervical intraepithelial neoplasia (eIN). The lesions appear
predominantly at the junction of the squamous and columnar
epithelium, known as the transformation zone. Here, the
columnar epithelium is replaced by metaplastic squamous
epithelium. The sexual transmissibility of these warts and
the high incidence of this condition led to extensive studies
on the pathogenesis of eIN (Nuova et al., 1987).
The oncogenic types of HPVs are known to be
causative agents in the pathogenesis of cervical cancer. More
than 90\ of the cervical carcinoma biopsies reveal the
presence of HPV DNA. The frequent detection of mRNA
transcripts for early proteins E6 and E7 of HPV 16 and 18,
strongly suggests the role of these proteins in the
transformation of cells. These early proteins have been
detected from cervical carcinoma cells in vitro. The
inability to demonstrate these proteins in vivo is believed to
be due to the low abundance of the proteins or masking of E7
epitopes in the nucleus by binding with cellular proteins,
oligomerization or self folding (zur Hausen, 1989; Smotkin &:
Wettstein, 1986; Grissmann, 1992; Kanda et al., 1991).
supportive evidence for the oncogenic potential of
the high risk HPVs has accumulated in abundance. Transfection
18
of HPV 16 and 18 DNA into primary human keratinocytes leads to
immortalization of the cells. while the low risk type HPVs
fail to immortalize keratinocytes. The immortalized cells
show aneuploid karyotype like the cells from premal igllClnl
cells (Woodworth et a1., 1989; Fu et a1., 1983). \\Then cells
immortalized with high risk HPV DNA were grafted beneath a
skin-muscle flap of athymic mice, the grafts exhibited
dysplastic morphology and molecular alterations in gene
expression, characteristic of intraepithelial neopl<lsia
(Woodworth et a1 .• 1990).
The HPV DNA of high risk types 16 and HI are
frequently integrated in cervical cancers and HPV positive
cervical carcinoma cell lines. The viral DNA integration has
been observed to occur in the general vicinity of known
oncogenes. In HeLa cells the integration of HPV 18 DNA occurs
at a site 50 kbp from the c-myc locus on chromosome 8. However
the significance of this integration pattern is not clear.
The viral D"JA from low risk HPVs are usually present
extrachromosoma11y in episomal form (Sang & Barbosa, 1992:
Durst et al., 1985: Durstetal., 1987),
The genes directly involved in the transformation of
primary human embryonic fibroblasts by HPV 16 were identified
to be E6 and E7. by transfecting subgenomic fragments of Hf'V
16 DNA under the control of SV40 promoter (Watanabe et a1.,
1989). Similarly, it was shown that full length HPV 16 E6 and
19
E7 genes are required and sufficient for transformation of
primary human keratinocytes (Halbert et al., 1991).
The knowledge about the association of E7 with pRB
and E6 bindir to p53, gave information about the possible
mechanism of tumorigenicity by E6 and E7. p53 mutations have
been observed in metastasized cervical carcinomas. indicating
the role of p53 in the pathogenesis of cervical cancer. It is
hypothesized that specific interactions of E6 and E7 with p53
and pRB abrogate the functions of these proteins in cervical
cancer by mutation of genes or by the binding itself. The E7
proteins encoded by the high risk HPVs bind pRB with higher
affinity than the E7 proteins of the low risk HPVs, suggestive
of the reason for the differential pathogenicity between the
high risk and low risk HPV types (Dyson et al., 1989; Crook &
Vousden, 1992; Schaffner et a1., 1991; Munger et al., 1991).
The role of glucocorticoid hormones in the transformation
process has been studied. The inhibition of the hormone
cl )pendent transformation of HPV 16 and ras was seen when baby
rat kidney cells were treated with the hormone antagonist RU
486 (Pater et al., 1988; Pater & Pater, 1991).
1. 2.3 The Regulatory Region' pf UPV Gftnmge
In most cervical carcinomas and tumor cell lines, HPV
DNA is found integrated into the host genome leading to
20
disruption of the El and E2 ORFs. The absence of these gene
products is believed to cause deregulation of E6 and E7
expression, since E2 is the known repressor of E6 and E7
transcription. Thus, t.he expression of integrated HPV DNA is
not regulated by HPV encoded proteins. After integration into
host genome, E6 and E7 are regulated by host factors. Unlike
the integrated DNA, episomal DNA is regulated by HPV encoded
proteins (reviewed in McBride et a!. 1991).
In the absence of any viral gene product, HPV lR
noncoding region (NCR} can function as a transcription control
element in many cervical cell lines (Thiery &. Yaniv, 19w1).
In all papillomaviruses, the NCR/upstream regulatory region
(URR) has the replication and transcription regulatory
regions. This is believed to regulate expression of the HPV
ORPs. This NCR!URR is present between the end of the late QRP
and the start of the E6 gene (Ga~'cia-Carranca et al. BRH).
There has been much interest in investigating the role or: the
NCR due to its ability to direct transcription of the
downstream ORFs.
1.2.4 Role of the MeR in the Exprenion of HPY U
The URR of HPV 18 has three distinct enhancer
elements. Two of the enhancers are inducible by HPV 18 gene
products, while the third enhancer does not require any HPV 1ij
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gene product. This enhancer is termed as the minimal
constitutive enhancer (MeE). The MCE is 230 bp long, present
between the two inducible enhancers (see Fig 1.). The 38B bp
enhancer present adjacent to the Ll ORF is the least conserved
enhancer. This enhancer is believed to be involved in the
viral gene expression when HPV 18 is in the episomal form.
When integrated into host genome. in malignant
transformation of the cells, the HPV genome is not under the
control of the E2 gene product. Viruses expressing only the
86 and E7 genes are known to be better transforming agents
relative to the entire viral genome. The 237 bp enhancer
element is present close to the E6 QRF. This element has TATA
and CAAT boxes for RNAP II binding (Gius et al., 1988; Swift
et al., 1987; Ward et al., 1989)
The constitutive enhancers of HPV 11, 16 and 18 are
capable of activating expression of heterologous promoters to
high levels in squamous epithelial cells in transient
transfection assays. This suggests the role of the
constitutive enhancers in the tissue tropic expression of HPVs
(Mack & Laimins, 1991). Epidemiological studies indicate that
HPV 18 is a particularly high risk virus. The incidence of
tumor recurrence is higher with HPV 18 than with HPV 16. The
virus is found to be associated more commonly with invasive
The onset age is usually less by 10 years with HPV
18, compared to cancers caused by HPV 16. Lesions with
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adenocarcinoma and small cell carcinomas are more associated
with HPV 18. Infection with HPV 18 is therefore believed to
cause rapidly progressive cancers of the cervix (Stoler. M.H.
et al., 1992). When chimeric constructs of HPV 16, 18, E6 and
E7 ORFs with SV40, HPV 16 and HPV 18 URRs were used in
transformation assays, the construct with HPV 18 URR showed
the highest immortalization efficiency. This indicates that
the URR upstream of E6 and E7 is the major determinant of the
differential immor.talization activities of HPV 16 and HPV lR
and HPV 18 URR!E6/E7 is more efficient than the analogol,w
region of HPV 16.
1. 2.5 CeUulnr FActOrs Bind to the DPY 18 MeE
DNA-protein binding assays have demonstrated the
binding of cellular factors to the HPV 18 MCE, as shown in fig
2. The imporLance of the MCE in the regulation of HPV
expression in transformed cells has attracted extensive
research in understanding this mechanism. Though the vast body
of data has aided in understanding this intricate process. an
unambiguous explanation is not available.
Three nuclear factor 1 (NFl) motifs have been
identified in the HPV 18 MCE. NFl is a DNA binding protein
recognizing the CCAAT box. It is known to be important in the
activation of cellular genes and DNA replication.
Fig 2.
Diagrammatic representation of celluar factors binding to the
230 bp HPV 18 minimal constitutive enhancer (nucleotides 7508-
11)8). API, NFL Oct- 1 and KRF-1 are the factors known to
bind to the MCE (Hoppe-Seyler and autz,1994l. The proposed
binding of the "ACTGCT binding protein" is also depicted.
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Experiments with the HPV 16 URR indicated the importance of
NFl sites in the regulation, in association with API. The
glucocorticoid responsiveness of HPV 16 enhancer is said to be
partially dependent on the presence of NFL Though ubiquitous
in distribution, NFl is argued to be important in the cell-
specific function of the HPV 16 enhancer. However, the
contribution of NFl in the control of expression of HPV 18 URR
is found to be only marginal (Chong at al., 1990; Apt et al.
1993; Butz & Hoppe-Seyler, 1993).
Both HPV 16 and HPV 18 URRs have aC"l;vator protein
1 (AP!) elements. While HPV 16 has 3 binding sites, HPV 18
MCE has one element and another in an inducible enhancer. AP!
is a heterodimer of protooncogene products of jun and tos.
AP1 is a transcription factor isolated from HeLa cells and is
identical to the human jun gene product. AP1 is believed to
be important in the expression of HPV 18 URR. In terminally
differentiated cells, jun B homodimers are the APl elements
involved. A recent study suggests the possible role of an
unidentified factor present in C33A cells that is essential
for activation of HPV 18 expression in association with jun B
(Chong et al., 1991; Vogt & 80S, 1990; Thierry et al., 1992).
The octomer-binding transcription factor-1 (oct-l)
has two low affinity binding sites on HPV 18 URR. One oct-1
site overlaps with the recognition sequence of KRF-1 and
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represses enhancer activity. Mutation of the oct-l site at
the 3' -end of HPV 18 MCE did not show an effect on the
activity. Oct-l is abundantly expressed in proliferating
transforming cells. The site present in HPV 16 URR exhibits
opposite effects in cervical and non-cervical cells. While it
inhibits gene expression ih non-cervical cells, a novel
octomer binding factor present in cervical cells is believed
to activate expression by displacing oct-l (Hoppe-Seyler &
Butz, 1994; Morris et aI., 1993).
KRF-l is a keratinocyte-specific transcription
factor, known to bind the HPV 18 MCE. There is no known KRF'-l
binding site on the HPV 16 URR. The specific distribution of
this factor in keratinocytes is argued to be the reason for
HPV 18 expression in keratinocytes. However, HPV 16 which is
also a tissue tropic virus, does not have any control in its
expression, from KRF-l (Mack & Laimins, 1991; Hoppe-Seyler I<
Sutz, 1994).
The HPV 16 URR has three motifs for transcriptional
enhan.::er factor (TEF)-I, which is present in keratinocytes and
cervical carcinoma cells (Ishiji et aI., 1992). A cellular
zinc-finger protein YYl is believed to have a repressing role
on HPV 18 expression. The deletion or mutation of this site
in cervical carcinomas is hypothesized to be the mechanism in
the development of carcinoma (Hoppe-seyler I;. Sutz, 1994).
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1. 3 Objective. Qf tho Study
wi th the knowledge about the important role of the
HPV 18 MCE in cervical carcinoma caused by the high risk HPV
18. the aim of this study was to understand the molecular
mechanism involved in the regulation of HPV 18 MCE using C33A
cervical carcinoma cells. The studies were performed using
C33A cells, since they do not contain HPV DNA, thereby ruling
out the involvement of virally encoded factors. This provides
an environment to investigate the activity of HPV 18 MCE and
its regulation by the host cellular factors.
The working hypothesis was that the identification
of the MCE region most significant in regulating the activity
of HPV 18 would be the first step towards meeting the
objective. This region would then give information about the
protein(sl binding to this fragment and the role in the
regulation of HPV18 expression. The successful delineation
of the MCE would then direct further attempts at identifying
the protein(s) most important in the tissue tropism of the
virus.
Earlier work by Dr. Pater's lab had identified five
DNase! protected regions in the MCE of HPV IS.labelled as
regions I to V (Nakshatri et al .• 1990 I. The possible role of
an ACTGCT sequence present at nt 7679 to 7684 of region V of
the HPV 18 MCE was speculated by the authors. The absence of
2f1
this sequence in the non-oncogenic HPV 11, while also present
at nt 7545 to 7550 (If region I ill HPV 18 MCE and at nt 7579 to
7584 of HPV 16 MCE was an interesting observation. No known
transcription factor is known to recognize this sequence (
Faisst & Meyer, 19921.
Generation of unidirectional deletions of the MCE
from either end using exonuclease III was ... 'the first step ill
this direction. The deleted regions of the HPV lR MCE would
then be cloned upstream to the reporter chloramphenicol ucetyJ
transferase (CAT) gene. The in vivo activities of these
deletion mutants would be compared with the full length HPV If!
MCE by performing CAT assays using C33A cell extracts.
The aim of the study was also to identify factor:-{:,)
binding to the important region by DNA-protein binding ussayH.
With the information from the deletion mutants the next step
would be to perform site directed mutagenesis and identify the
motif of HPV 18 MCE important and thereby the factor that is
involved in the regulation.
CHAPTER :2
MAterials and Methods
2.1 HA.t..u:i.a.l.a
Dulbecco's modified Eagle's (DME) medium was
prepared according to Current Protocols in Molecular Biology
by i'liley lnterscience. Fetal calf serum (FCS), trypsin-EDTA
solution were purchased from Gibco-BRL. The C33A cell line
was maintained in the laboratory.
Restriction endonucleases were ordered from Gibco-
BRL with their respective lOx React buffers. T4 DNA ligase
and 5x premix, exonuclease III, mung bean nuclease, calf
intestine alkaline phosphatase were also purchased from Gibco-
BRL. Nick translation kit was obtained trom Gibeo-BRL.
Reverse transr;riptase was supplied by Life Science.
a(J2 P JdCTP and [l~SldATP were purchased from
Amersham. Nick columns were obtained from Pharmacia. Kodak
was the supplier of thin layer chromatography (TLC) plates and
x-ray films. Acetyl coenzyme A was obtained from Sigma and so
was poly (dt·-dC) .polyjdI-dCl double strand, sodium salt from
i:'harmacia.
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Muta-Gene Phagemid in vi tro Mutagenesis kit
purchased from Bia Rad. Sequenase version 2.0 T7 DNA
Polymerase Sequencing kit was obtained from USB. Synthetic
oligonucleotides were purchased from General synthesis anel
Diagnostics, Toronto and University Core DNA Service:'!,
University of Calgary, Calgary. 5-Bromodeoxyuridene was
supplied by Sigma.
Recombinant plasmid pTa! was constructed by
Marshall et al. (1989). The HPV 18 minimal constitutive
enhancer was cloned to pUC19 by H. Nakshatri. plasmids pAI0cat
and pSV2 cat were provided by B. Howard.
2.2 Cell Culture of C33A CellI
C33A cells were maintained in DME medium containing
10% heat inactivated FCS. For cUltur~ng purposes, a frozen
vial of C33A cells thawed in a ]7"C water bath,
centrifuged at 1,000 RPM with DME and 10% FCS and the
supernatant was discarded. The pellet of cells was then
resuspended with the medium and plated in a tissue culture:!
plate. After overnight incubation at ]7'"C the medium waH
discarded and the cells were washed with PBS and trypsinized.
After adding DME the cells were plated at 1:] in tissue
culture plates. The cells were maintained in culture by
passaging on alternate days. when the plates were confluent,
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2.3 RecombinAnt Plumids
The plasmid pAIOcat was used in transfections as
a negative control in chloramphenicol acetyl transferase (CAT)
assays. This lacks enhancer sequences but has 21 base pair
repeats and TATA box of SV40 cloned upstream of the
chloramphenicol acetyl transferase gene (Laimins et al. 1982).
The plasmid pSV2cat (Gorman et a1. 1982) has SV40
enhancer sequences and hence used as a positive control in CAT
assays.
The recombinant plasmid pTa! (fig. 3)
const.ructed by Marshall et a1. (19891. This has the 230 base
pair HPV 18 minimal constitutive enhancer (nucleotides 7508-
77381 cloned at the 8g1 II site upstream to the 21 base pair
repeats of the plasmid pAlOcat, which has the chloramphenicol
acetyl transferase reporter gene.
2.3.1 COPBtruc;tiop of POlation Mutant Plasmid.
Unidirectional nested deletion of the 230 base pair
long HPV 18 minimal constitutive enhancer was generated as
described previously (Henikoff, 1982), with modifications as
in the StrategeneR manual. The HPV 18 MCE cloned at the Xba
I site of plasmid pUC19 was used for this purpose,
Fig 3.
Schematic diagram of recombinant plasmid
pT81 , Amp is the ampicillin resistance
gene, CAT is the chloramphenicol acet.yl
transferase reporter gene, HPV 18 MCE has
nucleotides 7508-7738 (Marshall et al .• 1989),
J3
Schematic diagram of pT81
21 bp repealS +TATA box of SV40
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The double strand DNA specific enzyme exonuclease
III digests single strand DNA from a 3' end only and cannot
digest a blunt end or 3' overhanging end. To create
unidirectional deletion from region IV end towards region I of
the MCE:, restriction enzymes BamH I and Kpn I were used to
linearize the plasmid. The deletion mutants created with this
batch were labelled as pBK, according to the different time
period of the reaction. The extent of exonuclease III
deletion was controlled by the duration of the enzymatic
digestion and determined by sequencing (Sanger et a1 .• 1977)
The linearized DNA was taken at the rate of '3
Ilg/time point in 25 ul of Ix exo III buffer (50 mM Tris-Hel,
pH B. 0, 5 roM MgC12 , 10 Jlg/ml tRNA). The reaction was done at
room temperature by adding 5 units of exo III enzyme per pg of
linearized DNA. At regular time intervals, aliquots of
digested DNA were added to tubes with Ix mung bean buffer (30
roM sodium acetate, pH 5.0, 50 mM NaCl, 1 roM znc!" 50%
glycerol) and placed on dry ice. The tubes were then heated
at 6BoC for 15 minutes and placed on ice. Fifteen units of
mung bean nuclease diluted in Ix mung bean dilution buffer 110
mM sodium acetate, pH 5.0, 0.1 mM zinc acetate, 1 mM cysteine,
50% glycerol) was added to each tube and incubated at 30"C for
30 minutes. The reaction was stopped by adding 10 pI of I f~
Tris-Hel, pH 9.5, 20 pI 8 M Lie!. 4 pI of 20% 50S. The mung
bean protein was removed by phenol: chloroform extraction. The
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linearized deletion mutants were recircularized by overnight
incubation at 4°C after adding 2 units of T4 DNA ligase and
ligation premix.
To create unidirectional nested deletions from
region I towards region v, the pUel9 with HPV 18 MCE was
linearized by digesting with Sal I and Pst I. The exonuclease
III reaction was performed as explained. The mutants so
generated were designated as pSP.
The deleted fragments of the HPV 18 MCE thus created
were digested with EcoR I and Hind III, blunt ended and cloned
into plasmid pAI0cat at its Egl II site. Plasmids pBK831S,
pBK575 and pBK8110 had frag.nents from nucleotides 7508-7664,
7508-7640 and 7508-7589 respectively. Similarly, plasmids
pSP725, pSP936 and pSP9913 had nucleotides 7596-7738,7632-7738
and 7660-7738 respectively. The deletion fragments are
depicted in fig. 4.
2.3.2 COD.trvgt;igD o£ Mutant Plasmid by Site Directed
Mutagen•• .i'
The probable role of the ACTGCT sequence (nt 7679-
76841 was speculated by Nakshatri et al., (1990). The sequence
of the mutation to be generated was designed such that no
spacing change and no known transcription factor binding site
would be created as listed in the "compilation of vertebrate-
pig ,.
The schematic representation of the deletions and site
directed mutant.
pTa1: nucleotides 7508-7738
pBK8315: nucleotides 7508-7664
pBK575: nucleotides 7508-7640
pspn5: nucleotides 7596-7738
pSP936: nucleotides 7632-7738
pSP9913: nucleotides 7660-7738
Mutant pBB155 has a G at nucleotide 7680 instead of C present
in pT8l and nucleotide 7682 1s changed from G to A.
The arrows represent boundaries of the regions I-V.
The asterisks denote the mutated nucleotide generated by site-
directed mutagenesis.
pT81
pBK8315
pBK575
pBK8110
pSP725
pSP936
pSP9913
I II III IV V
+ + _LJ LJ__J + + +
7508 7536 7556 7577 7586 7603 7619 7637 7659 7673 7704
7664
7640
7589
7596
7832
7660
7738
pBB155 7508 766:;682 7738
~
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encoded transcription factors~ (Faisst & Heyer, 19921. To
enable an efficient and easier screening of the mutant clones,
a mutant oligonucleotide was designed to creat.e the
recognition site AGTACT for the restriction enzyme Seal in
place of the sequence ACTGCT present in the wild type HPV lR
MCE.
Wild type Hpyt a enhancer
Dt 7667-5' -CTAAGTAATAAAA.C.~TTTTAGGCAC-3'-7693
Mlltant Hey] a ephancer
Dt 7567-5' -CTAi\GTAATAAAA~TACTTTTAGGCAC-)'-7693
To generate the desired mutations of two nucleotides
in region v, the Muta-gene~ Phagemid in vitro Mutagenesis kit
was used. The kit was purchased from 8io Rad. The plaslnid
pUC19 with HPV 18 MCE and vector plasmid pTZ19U were digested
with Kpn I and Pst I. The HPV 18 MCE fragment and the
lineari;r;ed vector were eluted on Sand S· NA4S membrane uoing
the protocol provided therein. The eluted fragments were then
ligated by incubating overnight at l6"C with 'I"4 DNA ligase and
ligase buffer. This plasmid was used to extract uracil-
containing phagemid DNA by transforming into CJ 236 cells.
A synthetic oligonucleotide 5' -GTGCCTAAAAGTAC'M'1'T
ATTACTTAG-3' was used as the primer to generate the desired
mutation. In the mutant HPV 18 MCE, nucleotide 7680 was a G
instead of the wild type C, and nucleotide 7682 was converted
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to an A in place of a G (fig 4) without. altering the rest of
the full length of MCE. The mutation created a new recognition
site for the restriction enzyme Sea I and could be screened
accordingly. The mutation was determined also by dideoxy
sequencing (Sanger et al., 1977).
The Sma I - Hine II fragment of the mutated MCE
was cloned into the Bg1 II site of pAIOcat to be designated
as pBB155.
2.4 TranRfectiQD of C33A Cell.
Transfections were performed by the calcium-
phosphate method (Graham and Vander Eb, 1973). Eight hours
before transfection, confluent plates of C33A cells were
passed at 1:3 dilution. 10 1-19 of plasmid DNA in 50 1-11 of 0.1
X TE buE fer was added to 62 I-ll of 2M CaC1 2 and made to a
volume of 500 u1 with distilled water. A fine precipitate of
DNA was formed by mixing with 500 III of 2X HBS (O.28 M NaCl,
0.05 M HEPES, 2.8 mM Na 2 HPO. pH 7.1) under gentle bubbling of
nitrogen. The precipitates were let to stand for 10 minutes
before adding to the plated cells. The plates were then
incubated at 37°C in a 3% COl incubator. After 4 hours of
incubation, the medium was discarded and 1.5 ml of 15%
glycerol in 2>: HBS was added to the plates. The cells were
washed wi th DME after glycerol shock for one minute. Traces
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of glycerol were removed from the plates by three washes with
DME. The cells were maintained at 37"C with fresh DME
containing 10% calf serum for 48 hours before harvesting
(Gorman et a1. 1982).
2.5 Prepnutinn of cell Lysate.
The cells were washed three times with PBS before
adding 2 ml of Tris-EDTA-NaCl solution (0.04 M Tris-Hel pfl
7.4, 1 roM EDTA, 0.15 M NaCI). Cells were harvested with
rubber policeman and transferred to eppendorf tubes. 1'he
cells were pelleted by centrifugation at 4 u C for 30 seconds.
After discarding the supernatant, the cells were stored frozen
at _'lODe until further use.
Cell extracts were prepared by freeze-thawing the
pellet. A.fter thawing at 37°C, the cells were resuspended in
100 III of 0.25 MTris-HCl, pH 7.8. The tubes were t.hen placed
on liquid nitrogen for 5 minutes. The cells were subject.ed to
three freeze-thaw cycles with intermittent vortexing. After
centrifugation at 4"C for 5 minutes in an eppendorf mkrofuge,
t.he supernatants were collected in fresh tubes.
2.6 Chloramphenicol AcBtyl TrAnsferA" ABsey fCAT'
The CAT assay protocol described by Gorman et aI,
(1982) was followed to estimate the in vivo activity of the
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plasmids. The assay mixture was made to a final volume of 100
u1 with 10 Ul of cell extract, 1 Ul Uc chloramphenicol, 10].11
of 4 mM acetyl coenzyme A, 45 1-11 of 1 M Tris-Hel, pH 7.8 and
34 III of distilled water. The tubes were thp.n incubated at
37"C for an hour. 500 pI of ethylacetate was added to stop
the reaction and extract chloramphenicol. The tubes were
vortexed for )0 sees and then centrifuged at room temperature
for 1 minute. The supernatant organic layer was transferred
to fresh tubes and vacuum dried in a Savant aspirar..:..r.
The dried organic layer was dissolved in 15 1-11 of
ethylacetate and spotted on silica gel thin layer plates to be
run with chloroform-methanol (95:5) in an enclosed glass jar.
Acetylated and non-acetylated forms of chloramphenicol
separated by ascending chromatography. The TLC plates were
exposed to Kodak x-ray films in the dark and left at room
tempera ture. The spots of acetylated and non-acetylated forms
were cut and counted by liquid scintillation. Data were
expressed as the percentage of acetylated chloramphenicol
against non-acetylated chloramphenicol. The results of the
mutant plasmids were expressed relative to the CAT activity of
the wild type plasmid pT81.
2.7 Mobil.ity Shift A...y
2.7.1 Pr9poratign Qf t33A Nuclei
Nuclear extracts were prepared as described by
Hennighausen and Luban (1987). Forty 100 roM plates or
cultured C33A. cells were washed and scraped in lx PloiS
solution. The cells were harve~ted by centrifuging ilt IRaQ
rpm at 4°C in a Sorvall HB-4 rotor. The pellet of cell ~ was
resuspended in 10 volumes of chilled Dulbecco's phosphate
buffered saline and centrifuged 5 volumes of 0.3 M su~:rose in
Buffer A was added to the pellet. Buffer A constitutes 10 mM
HEPES-KOH at pH 7.9, 10 roM RCI, 1.5 mM MgCl l , 0.1 mM EGTA, 0.5
mM dithiothreitol (OTT), 0.5 mM phenylmethyl sulfonyl fluoride
(PMSF) and 2 ~g/ml each of antipain, leupeptin and pepstatin
A. The solution was transferred to a chilled Dounce glass
homogenizer placed in ice. The cells were lysed with R-l:.!
strokes with a B pestle. Lysis was continued after 0.3-0.4'1.
nonidet P-40 is added to the homogenate. The lysis of cells
was monitored using a microscope. The homogenate wa:J
transferred to prechilled tubes and centrifuged at 2500 rpm at
4°C. The pelle ted nuclei were washed twice in 0.3 M
in buffer A wi thout Nonidet P-40.
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2.7.2 Prepaution of Crude Nuclear Extracts
Nuclear extracts were prepared as described by
Hennighausen and Luban (l987). The nuclei prepared by the
method explained above were resuspended using an all-glass
Oounee homogenizer in 2.5 pellet volumes of 400 mM NaCl, 10 mM
HEPES-KGH at pH 7.9, 1.5 mM MgC1 2 , 0.1 mM EGTA, 0.5 mM DTT, 5%
glycerol and 0.5 mM PM5F. The nuclei were lysed with 10
strokes using a 8 pestle. The nuclei were gently stirred at
4"C for 30 minutes and centrifuged at 39, 000 rpm for 60
minutes in a 75 Ti rotor. The supernatant was dialyzed
against SO volumes of 20 mM HEPES-KOH, pH 7.9, 75 mM Nael, 0.1
ml>! EDTA, 0.5 mM OTT, 20% glycerol and 0.5 mM PMSF, for 2-4
hours. The extract was then centrifuged at 20,OaO rpm for 15
minutes to remove precipitate and lipid. The nuclear extract
was aliquoted and frozen at _70°C after brief freezing in
liquid nitrogen. The concentration of nuclear protein was
estimated by the Bradford method (1976) using Bio Rad kit.
2.7. 3 ~iQn o£ Radiolab.ll.d DNA ProbB!!
The DNA fragments that were used to make probes for
gel shift assays were generated by digesting the pUC19
plasmid containing the HPV 18 MCE with enzymes Hind III and
Sac I. The deletion mutant enhancers and site directed mutant
enhancer were also obtained similarly. The fragments
electroeluted from 1% agarose gel. Radiolabelling of the
probt,.,~ was done by endlabelling the Hind III ends wi th
o[J2 PJdCTP by reverse transcriptase. The reaction mix W"lS
passed through Sephadex G-50 columns to remove unincorporated
nucleotides from endlabelled DNA.
2.7.4 Protocol for MgbiHty Shift Aauy
20,000 cpm of radiolabelled probe was used for each
reaction. 300 fold excess of nonlabelled fragments were added
to the reaction wherever required, as specific competitors.
The EcoR I - Hind III fragment of pUC19 was used as compet itor
to the few flanking pUC19 bases present in the cloned enhancer:
fragments. 5 lJg of nuclear protein and 5 \.Ig ot double
stranded poly (dI.dC) were used in the reaction. The mmay
was performed as explained previously (Chodosh at al. 19Rfl)
The individual components were added in a final volume of 15
pi containing '.I pI of 12 mM HEPES-NaOH, pH 7.9, 4 mM Tris-HCl,
pH 7.9, 60 mM KCl, 1 mM EDTA, 10% glycerol, 0.6 mM OTT and ]00
pg/ml bovine serum albumin. The tubes were incubated at 30"C
for 30 minutes. The labelled probe without nuclear extCi.lcL
was used as negative control. The reaction mi xc:,; were
electrophoresed on 4% polyacrylamide gels at constant voltiJye,
in a cold room. The circulation buffer contained 6.6 rnl1 'rrir;~
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He! pH 7.5, 3.3 mM sodium acetate and 1 mM EOTA, which was
constantly circulated using a pump. The gel was transferred
to 3 nun filter paper, dried and exposed to x-ray film.
2.8 Protocol for IN crosslinlcinq MIAYs
The experiments were performed as described by
Chodosh et al., (1988). Complementary strands of synthetic
oligonucleotides with nucleotides 7667-1693 were annealed as
described elsewhere (Kadonaga" Tjian, 1986).
The 27 mer wild type strands were: 5'-CTAAGTAATAAA
ACTGCTTTTAGGCAC-3' and 5' -GTGCCTAAAAGCAGTTTTATTACTTAG-3' .
The two mutant oligonucleotides used were: 5' -eTA
AGTAATAAAAGTACTTTTAGGCAC-3' and 5' -GTGCCTAAAAGTACTTTTATTACT
TAG-3' .
The annealed oligonucleotides were nick-translated
with a e2p) dCTP, 5-bromodeoxyuridine, DNAse I, polymerase I and
dNTP mix. After incubating for 60 minutes at 16°C, it was
precipitated in 95% ethanol and 3M NaCl solution at _70°C by
adding 5 ]lg salmon sperm DNA. The probes were washed by
centrifugation, dried and used in W crosslinking assays.
The reaction was done similar to mobility shift
assay but with 75, 000 cpm probe, 10 ]lg of protein and 10 I-Ig of
poly (dI .de) . At the end of the incubation, the reaction
mixes were transferred to Nunc vials and covered with Saran
'6
Wrap. The vials were placed under a F'otodyne UV lamp with
emission wavelength of 310 nM and maximum intensity of 7000
llw/cm2 , for )0 minutes. To the vials, equal volume of 2x
loading buffer containing 25 ml 4x Tris-HCl/SDS pH 6.R, 20 1lI1.
glycerol, 4 9 50S, 3.1 9 OTT, 1 mg bromophenol blue in 100 lUl
was added. The vials were boiled for 3 minutes and lOilded on
to a 10\ sodium dodecyl sulfate polyacrylamide gel. As <l.
marker, commercially available prestained protein marker of
high molecular weight range, comprising of myosin heavy chain
- 200 kDa. phosphorylase b - 97.4 kOa, bovine serum albumin -
68 kOa, ovalbumin - 43 kOa, carbonic anhydrase - 29 kDa, 1"-
lacto globulin - 18.4 kOa and lysozyme - 14.3 kOa was loaded.
CRAP'l'ER 3
3.1 In Vivo AQtiyiti•• of the HPY 18 MCE Dolotion Mutant..
in CJJA Cells
In order to estimate the relative in vivo
activities of the deleted regions of HPV 18 MCE with the
full length MCE, the deleted regions were cloned upstream to
the reporter CAT gene, tri!lnsfected to C33A cells and CAT
assays were performed. Since C33A cells do not: contain HPV
DNA. the transfected HPV 18 MCE regions are under the ~.irect
control of the host cellular factors.
The recombinant plasmid, pTel was transfected by
the calcium phosphate method into C33A cells. The plasmids
pA10cat and pSV2cat were also transfected into the same
batch of C33A cells each time, as negative and positive
controls, respectively. CAT assays were performed to
estimate the in vivo activities of the plasmids in enA
cells. The CAT reporter gene is driven by the full length
HPV 18 MCE in plasmid pT81 and by SV40 enhancer in pSV2cat.
In plasmid pAlOcat, the enhancer is absent, with only the
promoter present. CAT assay, therefore, wa:;; used to measure
the enhancer activity in C33A cells.
Pig 5.
In vivo activities of deleted and mutant MCE relative to the
ar.tivity of the full length 2)Obp HPV 18 MCE in CJ3A cells.
The results were obtained from three experiments using DNA
from two plasmid preparations.The results are presented as a
" of pT8l activity. The corresponding regions of the MCE are
listed above each bar. The asterisks indicate mutation
generated by site-directed mutagenesis.
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Plasmid pTa1 showed high activity in the C33A cervical
carcinoma cells. Since the plasmid does not contain iln
enhancer element, the activity of pAIOcat was 10w(3.6 't,}. The
activities of the deletion mutants in C33A cells were measured
by transfecting the cells with the deletion mutant plasrnids
and performing CAT assays. The deletion mutants were cloned
into pAIOcat similar to the wild type plasmid pT81. Thi~;
enabled the estimation of in vivo activities of the deleted
regions of enhancer, relative to the function of the wild type
enhancer as shown in Fig 5.
The 230 base pair MCE of HPV 18 (nucleotides 7508-
7738) was designated into regions 1 to V as described
pr<::!viously (Nakshatri et a1. 1990). The wild type plasmid
pTa! had all the five regions intact. The CAT activity o[ pBK
8315 (nucleotides 7508-7664) was drastically reduced to only
6.5 percent relative to the activity of pT8l. This plasmid
had the MCE fragment with regions I to IV. 'rhe reduction ill
enhancer activity was most significant when region V was
deleted. This indicated the importance of the region V in the
MCE and factor(sl binding there in,to the overall activity of
the HPV 18 MCE.
Plasmid pBK575 (nucleotides 7508-7640) showed '5.3
percent activity in comparison to pTal. This plasmid had
regions I to III of the MCE. Similarly, plasmid pBKIHIO
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(nucleotide:; 7508-7589, containing regions I-II expressed
only 5.1 percent of the pTa1 activity,
The activities of the plasmids containing MCE
fragments deleted from region I towards region V were also
measured by CAT assays. Plasmid pSP725 (nucleotides 7596-
7738) contained regions III to V of the MCE. The activity was
46.9 percent of the full length MCE. The regions I, II and
III were deleted and cloned in plasmid pSP936 (nucleotides
7632-7738) The CAT activity of this plasmid was 17 percent
to that of pTal. Plasmid pSP9913 (nucleotides 7660-7738l
containing only region V showed 9.16 percent activity as
compared to pTB 1 .
The activity of p5P9913 containing region Valone was
almost twice that of plasmids containing the other regions but
lacking the region V (pBK8315. pBK57S, pBK8ll0l, suggestive of
the importance of region V in the HPV 18 MCE activity.
Since the plasmid pBK83l5 (nt 7508-7664) containing
regions I-IV without region V showed a drastic reduction in
activity, this indicates the importance of this region in the
function of the HPV 18 MCE.
3.2 Gel Retardation Allays to Study DNA Protein Interoc;;tions
in Region y of DPY 18 MeE
After analysing the in vivo activity of the regions
of MCE, the next objective was to investigate the DNA-protein
"
interactions involving the region V which has' an important
role in the activity of the MCE as demonstrated by the CAT
assay resul ts.
To inv.astigate the rol~ of DNA-protein interactions
of region V with the cellular factors present in C3)A cells.
gel retardation assays were done using C33A nuclear extracts
(see Fig 6). The full length 230 base pair MCE was Ll1so used
to study the protein interactions.
The deletion mutant enhancer fragment BK8315, which
had nucleotides 7508-7664, was used to examine the effect of
region V deletion on DNA-protein binding. This fra~ment had
regions I-IV only. The fragment SP9913 containing nucleotides
7660-7738 has only the region V intact. This fragment was
also used in gel retardation assays. The EcoR I - Hind II I
fragment of pUC19 vector was used as a competitor to the few
bases of the polylinker region present flanking to the
enhancer. In competition studies, nonlabelled fragments of
BK8315 (regions I-IV) and SP9913 (region VI were separately
added in reactions containing the labelled full length MCE
probe to identify the specific binding to the region V.
Gel retardation of the HPV 18 full length MCE with
C33A nuclear extracts consistently showed two distinct bands
as shown in lane b in Fig 6. When nonlabelled MCE fragment
was used as competitor, the bands were clearly competed (lane
d). Competition with pUC19 polylinker sequence did not alter
Fig 6.
Gel retardation assay of HPV 18 MCE and deletion mutant
enhancers BK831S (regions I-IV) and SP9913 (region V) with
C3)A nuclear extract. )00 fold excess of non labelled
competitor was added wherever indicated.
a: 230bp HPV 18 MCE (wild type) probe alone.
b: wild type probe with C33A nuclear extract.
c: polylinker region of pUC 19 with b.
d: nonlabelled wild type fragMent with b.
e: nonlabelled BK831S fragment with b.
f: nonlabelled SP9913 fragment with b.
g: BKB31S probe alone
h: BK831S probe with C33A nuclear extract.
i: polylinker region of pUC 19 with h.
j: nonlabelled BKB31S fragment with h.
k: SP9913 probe alone.
1: SP9913 probe with C33A nuclear extract.
m: polylinker region of pUC 19 with 1.
n: nonlabelled SP9913 fragment with 1.
I
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the binding pattern (lane c) I thereby demonstrating the
specific binding of the proteins with the MCE sequences.
Binding assay with the BKB315 (regions I-IV) fragment
showed only the slower migrating complex (lane h). This
complex was competed when the nonlabelled BKB31S fragment was
added to the reaction (lane j). The band was visible whel".
::ompeted with puel9 polylinker fragment (lane i). When this
BRa31S fragment was used as a competitor with labelled full
length probe (lane e). only the faster migrating complex was
present, whereas the slow migrating complex was absent. This
(lanes h I e) demonstrates the association of the slower
migrating complex (upper) with regions I-IV of MCE.
When the SP9913 fragment containing only the region
V was used, the slower migrating band was not observed (lane
1). Only the faster migrating band was seen which was not
affected by competition with pUCl9 polylinker sequences (lane
ml,while competition with nonlabelled SP9913 did not show any
band (lane n). When this region V fragment was used as
competitor with the full length MCE (lane f), the faster
migrating complex was greatly reduced, whereas the upper band
was slightly reduced. This (lane L fl demonstrates the binding
of the faster migrating complex (lower) to region V.
The ge::' retardation assays demonstrated two distinct
complexes bindin9 to the 230 base pair MCE. The binding of
region V was specific to the faster migrating band and the
56
slow migrating complex showed interactions with regions I to
IV. The binding assays underlined the specific interactions
of a protein comp"ex with region V of HPV 18 HCE:. correlating
its in vivo activity in C3)A cells. This demonstrates the
binding of a protein complex to the region V • suggestive of
its role in regulating the in vivo function of the region V.
3.3 In yivo Ac;t,iyity of the Site Directed Mutapt
With the identification of region V as an ilnPO~·tdllt
region for the activity of the HPV 18 MCE , as demonstrated by
in vivo CAT assays and the subsequent experiments on DNA -
protein binding which indicates the spec fie association of
C33A nuclear factors with region V • the first objective of
the project was addressed. The next aim was to identify the
sequence of this region V that is specifically involved in
regulating the MeE activity.
The probable functional role of the ACTGCT sequence was
speculated by the Pater's group I Nakshatri et al. • 19901.
The presence of this sequence in the MCE of the oncogenic Hf'V
18 and HPV 16 and its absence in the non oncogenic HPV 11 WilS
an interesting observation This sequence is not known to be
recognized by any transcription factor (Faisst '" Meyer •
1992) .Since the region V was found to be important for the
activity of MCE • the ACTGCT sequence present at nt 7679 -
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7684 was hypothesized to be essential. To elucidate the role
of this sequence. site directed mutagenesis of this sequence
was performed on the full length MCE. While designing the
mutation, care was taken not to create a known recognition
site. For an easier and efficient screening of the clones, a
restriction site AGTACT for the enzyme Sea I was created.
This mutant plasmid pBB155 , containing the mutant
sequence AGTACT at nt 7679-7684 instead of the wild-type
sequence ACTGCT. without changes in the rest of the full
length MCE was transfected into C33A cells and CAT assays were
performed (fig.5) to investigate the importance of this ACTGCT
sequence in the HPV 18 MCE activity in C33A cells. The CAT
activity of this mutant plasmid was drastically reduced to the
extent similar to that expressed by deletion mutant plasmid
pBK8315 (rl2!gion V) as shown in Fig. 5. This demonstrates the
importance of the ACTGCT sequence Cnucleotides 7679-7684) in
the in vivo activity of the HPV 18 MCE.
3.4 Gel Retardatign using the Site Directed Mutant
The demonstration of the important role in the
regUlation of the MCE activity by the ACTGCT ( nucleotides
7679-7684), warranted further investigation in this regard.
To address the involvement of DNA-protein interactions within
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this short region of DNA, gel retardation assays
performed (Fig 7) .
The 230 base pair full length MCE fragment was used
in gel retardation experiment with C3JA nuclear extract (lane
bl. Again, two distinct bands were present . When polylinker
sequence of pUC19 vector was used as competitor, the bands
were present (lane c). The bands were absent when non
labelled full length MCE was used as specific competitor (Jane
d I.
The addition of the mutant fragment 8B155, which had
the 2]0 base pair full-length MCE with mutations only at
nucleotides 7680 and 7682, to the reaction (lane e) competed
the slower migrating (upperjband but not t.he faster migrating
(lower) band, indicating the inability of the mutant region to
form a DNA-protein complex while the rest of the MCI:: bind:~
to the proteins, thereby abrogating the slower migrating band
only. When the mutant BBl55 probe was used in g~l
retardation assay, only the slower migrating (upper) band WM~
present (lane g). The binding pattern was similar to the gel
retardation experiments done wit'l the deletion mutant OKfl315
containing regions I-IV (lane h,Fig. 6) The addition of non
labelled mutant 88155 to the reaction competed the complex
(lane h) This (lane e,g) demonstrates the sDecific binding
of a cellular factor to the ACTGCT motif, which is abrogated
by the site directed mutation.
Fig 7.
Gel retardation assay using wild type HPV 18 MCE and mutant
BB155. 300 fold excess of non labelled competitor was added
wherever indicated.
wild type probe alone.
b: wild type probe with C33A nuclear extract.
c: polylinker sequence of pUC19 wi th b.
d: nonlabelled wild type fragment with b.
e: nonlabel1ed mutant BB155 fragment with b.
E: mutant BB155 probe alone.
g: mutant BB155 probe with C33A nuclear extract.
h: nonlabelled mutant 88155 fragment with g.
·abc d e. i 9 h .
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3.5 uy CroB8linkinq to Identify t.he Factor :rnterac;tinq with
the Mutont RAgign
since the gel retardation assays were done using the
full length MCE and mutant MCE, UV crosslinking experiment was
performed using synthetic oligonucleotides of nt 7667-7693, to
further investigate the effect of the mutation in the DNA
protein intel.3.ctions (Fig B). Complementary strands of wild
type and mutant synthetic oligonucleotides containing
nucleotides 7667 to 7693 were annealed, labelled and
crosslinked with C33A nuclear extract.
While the wild type oligonucleotides demonstrated an
intense band correspondbg to a 40 kOa protein (lane b), there
was an abrogation of this band when mutant oligonucleotide
strands were used (lane cl. While wild type oligonucleotides
shows faint bands between 91 and 200 kDa, these were not
consistently observed in repeated experiments. The absence of
the 40 kDa band in the reaction with mutant oligonucleotides
was a consistently reproducible observation,indicative of the
inability of a 40 kDa protein to bind to the mutant sequence.
Experiments with the addition of nonlabelled mutant
oligonucleotide with labelled wild-type oligos would be a good
control. An oligonucleotide with multiple repeats of the
ACTGCT sequence can be used to identify the specific protein
binding to tllis sequence.
pi" 8.
W crosslinking of wild type and site directed mutant
oligonucleotides with C33A nuclear extract.
wild type probe alone.
b: wild type probe with C33A nuclear extract.
c: mutant probe with C33A nuclear extract.

CHAPTER 4
4.1 Importange Qf tbe Minimal constitutive Enhancer
The important role of the promoter and enhancer
elements in the control of HPV 18 gene expression is well
documented (Gius et al., 1988; Thierry et al. 19R7; Butz [,
Hoppe-seyler, 1993). The 230 base pnir MCE of HPV 18 is known
to be cell-type specific. The control of this enhancer doe~
not involve any HPV 18 encoded gene product (Swift et al.,
1987; Marshall et al., 1989). Since the C33A cells used ill
this project does not have HPV DNA integrated into the genome,
the studies were performed without the overlaying ef. fects or
viral encoded factors on the function of the MCE.
HPV 18 is more efficient in the immortalization or
epithelial cells than HPV 16. It is also associated with the
rapid progression of invasive cervical carcinomas (Kurman et
al., 1988). The increased immortalization potential of HPV 18
is believed to be conferred by its upstream regulatory region,
which contains the MCE (Rolllanczuk et <11. 1991). The
interaction of cellular proteins with the enhancer element is
well established (Garcia-Carranca et al., 19BB; Glm;s et ill.,
1989; Nakshatri et al., 1990). The importance of. cellula!
factors in the regulation of HPV 18 expression attracted
attention in the pursuit of understanding this molecular
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mechanism. To address this question, the objective of this
project was to identify the important region of the MeE and
thereby the factor that plays a dominant role in this
mechanism.
4.2 SiqnifiCiDngfl Qf the Deletion~
unidirectional deletions of the MCE from either ends
were generated to delineate the region most important. for its
function. Among all the deletion mutants, the deletion of
region V showed the most reduction in activity. The plasmid
pBK 8315 (l1ucleotides 7508-7664) containing region V had only
6.5 percent of the full length activity (Fig 5). This drastic
reduction in the activity indicates the important role of
region V of the MeE. Increased deletion of the enhancer
towards region I did not show II further reduction in activity.
An NFL binding sequence is deleted in pBK831S. The reduced
activity could be argued to be due to the absence of this NFL
binding to its motif. However, this is unlikely to be the
reason, since NFL is known to contribute only marginally to
transcriptional activation (Gloss et al., 1989; Butz & Hoppe-
Seyler, :;'993). A Oct-l binding site is also deleted in this
mutant. But th~ inability of OCt-l to bind would not lead to
this reduced activity, since Oct-l reportedly represses the
enhancer activity (Mack & Laimins. 19911.
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The deletion mutant pSP725 (nucleotides 7596-7738)
containing regions III~V demonstrated 46 percent of pT81
activity. The deletion of two NF-l binding sites present in
regions I-II could not have contributed to this reduction, due
to its known marginal contribution to the enhancer activity
(Butz & Hoppe-Seyler, 1993). Int.erestingly, there is an
ACTGCT motif at nucleotides 7545-7550, which has been deleted
in mutant pSP725. This could be the possible reason for the
slight reduction in the intensity of the upper complex in lane
f of Fig 6, when region V fragment. is used as a competitor
wit.h labelled full length prtJoe. Since the importance of the
ACTGCT sequence present at nt 7545-7550 has not been
investigated by site-directed mutagenesis,it is not possible
to analyse its involvement. However, the reduction in CN/'
activity is quite significant, since more than 50% of the
activity is lost. In addition to the ACTGCT sequence,only two
NF-1 binding sites are deleted in this mutant (pSP725). Both
the NF-l sites are half site NF-I recognition motifs and are
believed to be poorly bound by NF-l. Mutation of both the NF-l
sites did not lead to a strong reduction in the activity of
the MCE,indicating the lesser role of these NF-l sites (Butz
& Hoppe-Seyler,1993). This suggests a possiblE.· role of this
ACTGCT sequence, which can be addressed by further studies.
The mutant pSP936 has regions IV-V ( nucleotides 7632-
7738). It expresses only 17 percent of activity relative to
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pT81. In addition to the two NF-l sites. ACTGCT motif. an API
site is also deleted (Offord & Beard, 1990). API sites are
known to be essent.ial for the HPV 18 HCE: activitylThierry et
a1.. 19921. A recent study demonstrated the role of Jun B as
the predominant Jun component complexing with API elements.
Mutational Ilnalysis of this API site established it.s
importance in HeLa and HaCAT cells. However, mutation of the
APi site re3ulted in a less drastic reduction in the
transcriptional activity in C33A cells than in keratinocytes.
It was suggested that in addi tion to the API, a yet to be
identified factor is important in C33A cells (Offord & Beard,
1990; Thierryet a1.. 1992; Sutz & Hoppe-Seyler. 1993). The
mutant pSP9913 containing region V (nucleotides 7660-7738)
has binding sites for NFl and OCt-I. The reduced activity
could be due to the delet.ion of two Oct-l sit.es, t.wo NFl sit.es
and API element (Mack & Laimins, 1991; Gloss et. al., 1989;
Offord' Beard, 1990). Also, an octOlMr mot.if at. nucleotides
7731-7738 in region V has been reported to inhibit HPV 18
expression in cervical cells by inhibiting the binding of NFl
t.o its sit.e at nucleotides 7731-7735 (Morris et aI., 1993).
It is important. to note that the act.ivity of the
plasmid pSP9913 containing the region Valone is almost double
that of the plasmids(pBK831S, pBK575, pBKBllO) containing
other regions of the MCE but without region V.
"
The in vivo assays using deletion mutants clearly
deIII,:,nstrate the importance of region V and is suggestive of
the rol.e of a novel factor present in C33A cells, in the
regulation of HPV 18 MCE expression.
The gel retardation assays using the wild type HPV 18
MCE and deletion mutants were performed to investigate the
DNA- protein intel"actions involved in the region V of the MCE
(see Fig 6). Since the deletion mutant BK831S has regie-os 1-
IV, the use of this fragement would show the interaction of
proteins with these regions. The use of SP9913 fragment
containing region V only was designed to demonstrate the
association of proteins with this region. Accordingly. two
co.nplexes were seen with the wild-type full length MeE: (lane
b). When the BK83lS fragment was used only t.he slower
migrating complex was observed (lane h). The reaction using
SP9913 demonstrated only the faster migrating complex (lane
1). Competition experiments were performed to identi fy the
specificity of the complex formation with the regions of MeE:.
t'lhen C33A nuclear extracts were incubated with nonlabelled
BRanS fragment before adding the labelled wild-type probe,
only the fas ter migrating complex was seen (lane 1). This
demonstrates the binding specificity of the slower migrating
complex to regions I-IV of the MCE. Similarly, when
nonlabelled SP9913 fragment was included in the reaction with
labelled wild-type probe, the slower migrat.ing complex WlIS
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abrogated while the faster migrating complex was observed
(lane f) . This shows the specific binding of region V to the
faster migrating complex. To rule out the possibility of non
specific binding, homologous nonlabelled fragments were added
in the reactions (lane d, j ,0). Nonlabelled pUC19 polylinker
sites were added as competitors to demonstrate the specific
binding of factors to the enhancer sequences (lane C,i,m ).
The use of deleted fragments with regions I-IV
(BRa31S) and region V (SP9913) along with wild~type full
length HPV 18 MCE in gel retardation assays using C33A nuclear
extracts demonstrated the formation of a specific DNA -protein
complex with region v.
4- • 3 Site pireotea MutAggnesis CORUnnA the :ImportAnce of II
ROyel FAptor
After delineating the region V as the important
region in the functional regulation of HPV 18 MCE activity. the
next obj ective was to identify the sequence involved in this
regulation. work done by the Pater's lab had speculated on the
possible role of the ACTGCT sequence in the function of the
HPV 18 MCE (Nakshatri et al.,1990). Since this sequence is
also present in HPV 16,but absent in the non oncogenic HPV 11,
the pursuit of investigation on this sequence seemed
attractive. The suggestion by Thierry et al.,{1992),on the
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involvement. of a novel factor in the regulation of HPV 18 MCE
in C33A cells is supported by the findings in the present
work, since no known transcription factor binds this
sequence{Faisst & Meyer, 19921. However. the findings of the
experiments performed in this study does not limit the
boundary of this motif to only six nucleotides.
The in vivo activity of the mutant plasmid pInUS5
was similar to the activity of the deletion mutant pBK8315.
Since only the ACTGCT motif was mutated without altering the
other sequences oJ: the HPV 18 MCE, this motif appears to have
an important role in the regulation. W crosslinking (Fig A)
with C33A nuclear extract demonstrates the inability of a
factor t.o bind to the mutant motif. thereby indicating the
illlportance of the ACTGCT motif for the interaction of a
protein factor with the DNA sequence.
Since the mutations do not create a change in the
spacing between nucleotides , a control construct wi th two
point mutations elsewhere in the MCE was not generated. Though
a reasonable rationale exists to perform this control the
generation of such mutant was not pursued To facilitate a
better screening efficiency, t.he design of the mutation was to
create the recognition site AGTACT for the rest.riction enzyme
ScaT. InterestinglY, t.he sequence created is a palindrornic
sequence The presence of a palindrome could lead to binding
of factors in dirners. Since t.he gel retardation assay and uv
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cross linking experiment demonstrated the abrogation of a
complex, this can be ruled out. The presence of a perfect
palindromic sequence in a double stranded DNA could lead to
the formation of a pair of hairpinned structures called
cruciform (Platt, 1955). It is plausible to believe that this,
formation can prevent the binding of a protein by structural \
inhibition rather than the change in the sequence. However,
elegant experiments by Courey & Wang. (1983) have demonstrated
that cruciform does not occur under physiological conditions.
Isolated plasmids containing 68 bp perfect palindrome were
found to be free of cruciform. The plasmid lacked cruciform
even in vivo. Therefore it is unlikely that this is happening
with the mutant plasmid used in this project. Moreover , the
mutant sequence AGTACT creates a Sea I recognition site which
was utilized in the screening procedure. Only plasmids
digested by SeaI enzyme were used for further cloning and
transfection. Th(~refore the reduction in the in vivo activity
and binding could be only due to the change in the \~ild type
ACTGCT sequence and not due to cruciform formation.
A recent study on the role of API elements on HPV 18
transcription has outlined its importance (Thierry et al.,
1992). However, it was observed by the authors that in C33A
cells the transcription was efficient, despite the low amounts
of API in the cells. It was speculated that an unidentified
factor played a predominant role in C33A cells. The
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suggestion was that Jun 8 would interact with an "unidenl:ifi~d
transcriptional factor" in regulating HPV 18 expression. 'I'he
cell type specificity of HPV 18 expression is believed to be
regulated by a multifactor phenomenon (Thierry et al., 199::).
A similar hypothesis has been proposed by !shiji et ill. (1992)
in the cell type specific expression of HPV 16. The protej n
identified as transcriptional enhancer factor (TEFl -1 W,l~;
shown to complex with the HPV 16 enhancer. A "TEF-J
coactivator" was believed to be associated with TE["-l in till.;'
regulation of HPV 16 expression in keratinocytes and cervicdl
carcinoma cells (Ishiji et aI., 1992) The dati) pre~ented
here suggest an important role of the AC'I'GC'l' mutH and
indicates the involvement of an "ACTGCT bindiny pcot0in" lABP}
in the regulation of HPV 18 expression. This appears to be a
novel factor with a significant role in the regulation o( 11PV
18 transcription in C33A cervical carcinoma cells. This factor
could mediate the regulation of HP~' 18 expres5ion, by it:,;
specific binding to the ACTGCT motif and also by ito
involvement in the assembly of the protein complex, that mi.yht.
be required for the full expression. Further experiment~; wi! t
elucidate the exact mechanism involved in the regulat.ion (d.
HPV 18 expression.
The cellular factors NF-l,Oct-l,AP-1 are known to be:
ubiquitous in their distribution, while the expression (Jt l-lPV
18 is evidently tissue specific. It is therefore logical 1:0
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infer that this tissue tropism is not regulated by these
cellular factors. Though KRF-l is hypothesized to be involved
in the tissue tropism, the differential expression of HPV 18
with mutated KRF-l site in HeLa and HaCat cells was not
correlated with a difference in the binding pattern of KRF-l.
The mutation of KRF-l site did not lead to a strong reduction
in the transcrpitional activity of HPV 18 in C33A cells{Butz
& Hoppe-Seyler,1993). It has been speculated by Mack &
Laimins, (1991) on the possible role of other unidentified
factors in stabilising and activating transcription of HPV 18.
Given these findings, the importance of the "ACTGCT binding
protein" appears to be attractive.
Cotransfection of Jun B expression vector with
reporter gene under the control of HPV 18 URR failed to show
expression in fibroblasts (Thierry et Cll., 1992). This
indicates the inability of Jun B to activate HPV 18 expression
in non epithelial cells. The expression of HPV 18 was found
to be very low when pTBl was transfected into 143B fibroblast
cells. This could be due to the lack of the ACTGCT binding
protein in 143B cells.
'The products of early genes E6 and E7 of HPVs are
known to be the oncoproteins involved in the transformation
and tumor formation. The E6 and E7 gen..> products of high risk
HPVs are adequate for inunortalizing primary rodent cells,
while these genes of the low risk HPVs fail to immot~.alize. E7
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alone is capable of immortalization unlike the E6 gene produ('t
which requires E7 for the successful immortalization. In
cooperation with activated Ras oncogene, the HPV oncoprotein::;
can induce a fully transformed phenotype resulting in tumor
formation in mice. In association with Ras, E7 alone can cause
transformation and is required for maintenance of the
transformed phenotype. The infection of target cells with 1,1PV
and the subsequent expression of the oncoproteins is believed
to be the first step towards tumor formation. The underlying
mechanism involved in this process is believed to be clue to
the binding of E6 and E7 to p53 and pRb. The E6 rrotein froll!
low risk HPVs does not lead to degradation of p53 like the E:6
protein from HPV16 and HPV lB. Unlike the E7 proteins from the
high risk HPVs, the E7 products of low risk HPVs bind pRb with
lesser affinity. The expression of E6 and E7 genes is
regulated by the E2 gene product. In benign lesions the HPV
genome is found in episomal form, while the HPV genome
integrates into the host genome in most malignant lesion!,;
(Mansur & Androphy, 1993; Munger et a!., 1991; Giur~ et (11.,
198B). The integration of the HPV genome leads to the
disruption of the E2 gene. The E6 and E7 are then regulated by
the upstream regulatory region (URR) which has binding siL:.c~.l
for many cellular factors (Garcia-Carranca et a!., 19RR)
Since the balance of the E2 products leads tQ
inhibition of transcription, the disruption of this contrf)l b
15
believed to lead to malignant change in the cells (Ward
a1 .• 1989). This increase in expression of oncoproteins is
mediated by t.he cellular factors that bind to the URR. It is
therefore important to understand the role of cellular factors
that interact with the MCE. It could be speculated that ASP
has an important role in this multifactor mechanism.
The cellular transcription factor Spl is believed to
be involved in the biology of papillomaviruses. The binding of
E2 protein to the HPV 18 URR is known to stcrically interfere
with stable formation of the preinitiation complex. Spl is
known to displace the binding of E2 and thereby leading to the
activation (Hoppe-Seyler & Sutz. 1994). It could be speculated
that ASP contributes to the stabilization of the transcription
machinery by interacting with the adjacent cellular factors.
The HE'\! 18 URR has a binding site for a cellular
zinc-finger protein YYl close to the GRE. The binding of the
YYl factor to this negative regulatory region of the HE'\! 18
URR leads to repression of the E6/E7 promoter. The YY1 binds
to the silencer element with high affinity to negatively
regulate the F.6/E7 promoter. This repression appears to be
overcome in some carcinomas by mutation or deletion of this
region (Sutz 6< Hoppe-Seyler, 1993; e,,"ukneckt et ,,"1., 1992).
It is tempting to speculate the possibe role of ASP in
inactivating this silencer whenever it is present without
alteration, thereby leading to the expression of £6 and £7.
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This could be one of the mechanisms employed by the vi UIS to
escape cellular control and thereby cause maligllant.
transformation.
In summary, the ACTGCT motif lnucleotides 7679-76Atl)
present in the HPV 18 MCE appears to be importdllt ';lIld
indicates the role of a novel AeTGCT binding protein (ABP} ill
the regulation of HPV 18 expression in C3]A cells. '1'110\1911 the
presence of the ACTGCT sequence alone is not:. sufficienl" l:lJ
activate transcription, the mutation of this binding mol i I
leads to a drastic reduction in the activity, suggcsUve or
it.s requirment for the overall activity of the HPV 18 Mel':.
Future Directions
The significance of thi.s protein needs to be [urthcr
investigated. While the present work deals ..... ith the AC'I'CC'I'
sequence present at nt 7679-7684. it would be inter:estinH to
mutate the ACTGCT sequence of HPV 18 I~CE pr:esent at nt 'niJl'j
7550 and study its activity. Both in vivo lind ill vil/"
changes need to be estimated. A plasmid with llIutatiom; in
both ACTGCT sites and API element would be useful in knowing
the interactions between the two factors. since the mutation
of API alone does not lead to a significant change in the HI'V
expression in C3JA cells, the requirement of the novel f;Jf~tr)f
can be demonstrated.
77
The isolation and characterization of this factor
from C33A cells will be useful. An oligonucleotide with
multiple repeats of ACTGCT motif can be used as the probe to
screen a C33A eDNA expression library. Functional analysis of
the protein will further aid in the understanding of its role
in transcriptional regulation.
An ACTGCT motif is present in the HPV 16 MCE also.
No factor is known to bind at this site (Nakshatri et
.011.,1990) Gel shift assay using that region will indicate
the presence of a DNA-protein complex. Further analysis by
site directed mutation can also be done. These studies would
help in understanding the role of this motif (and the factor)
in the regulation of HPV 16 MCE in addition to its role in HPV
18 MCE which is evident from the present study.
Immortalized cells of early passage can be used for
transient assays to look into the in vivo activity of HPV 18
MCE in these cells. Comparative studies could be done on the
role of ABP by performing CAT assays using both the wild-type
plasmid and mutant plasmid using cervical carcinoma cell lines
and also in immortalized c~lls of early passage. simultaneous
binding assays should be done. The status of HPV DNA in the
host cells must be analyzed. The effect of the tr3nsformation
status of cells on the regulation of HPV 18 MCE by ABP can be
addressed by these experiments.
7R
The effect of the factor on HPV 18 expression could
be due to t.he differential distribution of the protein.
Mobility shift assays using nuclear extract from different
cell types will indicate whether the protein is ubiquitous ot"
cell specific. The (increased) /presence of this filetor might
be a cause or effect of malignant transfor1l1.:l.tion/IIPV
expression. The eDNA of the gene can be used ill
cotransfection assays in cells that do not activate IlPV lR
expression/lack the protein.
The understanding about the regulatory role ilnd
tissue distribution of this protein might help in e1 ueidat i 119
the mechanism of HPV 18 expression and lIlill ignalll.
transformation. With the knrwledge about this proceSB, the
clinical relevance of this factor can be understood.
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